Controversies in Testicular Cancer Management: Evidence Synthesis, Competing Hypotheses, and Decisive Study Designs

Introduction

Testicular germ cell tumors (GCTs) represent one of oncology's most compelling success stories, with cure rates exceeding 95% for early-stage disease and approaching 80–90% for advanced presentations, depending on risk group and treatment response 17. Yet this very success has generated enduring management controversies: when cure rates approach 100% regardless of strategy, the clinical imperative shifts from maximizing survival to minimizing the treatment burden borne by patients who may live for decades after diagnosis. The following narrative review synthesizes pivotal and contemporary evidence on four major controversies in stage I seminoma and non-seminomatous germ cell tumor (NSGCT) management, identifies the strongest evidence supporting competing approaches, and proposes decisive study designs to resolve remaining uncertainties.

Controversy 1: Surveillance Versus Adjuvant Carboplatin in Stage I Seminoma

The debate. Approximately 80–85% of patients with clinical stage I seminoma (CS I SGCT) are cured by orchiectomy alone, meaning that adjuvant therapy—whether radiotherapy (RT), single-agent carboplatin, or intensive surveillance—will overtreat the majority 38. The fundamental question is whether the reduction in relapse risk conferred by adjuvant carboplatin justifies its toxicity and cost in a population where salvage chemotherapy is highly effective.

Evidence for surveillance. Prospective surveillance cohorts demonstrate an actuarial relapse risk of 12–20% at five years, with a small subset (approximately 4%) relapsing beyond year five 2. Cancer-specific survival (CSS) on surveillance approaches 99%, and the TRISST (Trial of Imaging and Surveillance in Seminoma Testis) phase III trial—enrolling 669 patients with median follow-up of 72 months—demonstrated that advanced relapse (Royal Marsden Hospital stage IIC or greater) occurred in only 1.5% overall, with five-year overall survival of 99% and no tumor-related deaths 23. Critically, a systematic review and meta-analysis of 88,863 patients found that surgery alone carried no increased secondary malignancy risk (standardized incidence ratio [SIR] = 0.99), whereas chemotherapy (SIR = 1.65) and combined modality therapy (SIR = 2.73) imposed meaningful carcinogenic burdens 6. A refined European Association of Urology (EAU) individual patient data analysis of 1,016 patients identified that 56.4% of CS I seminoma patients fall into a low-risk group with a five-year relapse probability of only 8%—a cohort for whom surveillance is the most justifiable approach 3. The National Comprehensive Cancer Network (NCCN) 2025 guidelines strongly prefer surveillance for all patients able to comply with the schedule 38.

Evidence for adjuvant carboplatin. A landmark randomized controlled trial (RCT) of 1,477 patients with stage I seminoma comparing RT (n=885) to single-cycle carboplatin at area under the curve (AUC) ×7 (n=560) demonstrated noninferiority: five-year relapse-free survival (RFS) was 96% versus 94.7%, respectively (hazard ratio 1.25; P=0.37), with one seminoma-related death in the RT arm and none in the carboplatin arm 38. Patients receiving carboplatin reported less fatigue and were less likely to require time off work than those receiving RT 38. An early retrospective series of 107 patients treated with two cycles of carboplatin reported zero recurrences at median 74-month follow-up 1. A multicenter Spanish dual-policy study confirmed that adjuvant carboplatin reduced the five-year relapse rate to 3.3% in high-risk patients versus 16.1% in surveillance controls 4. The EAU risk stratification model identifies a high-risk subgroup (2.3% of cohort) with a 44% five-year relapse probability—a group where adjuvant intervention appears clearly justified 3. EAU guidelines position single-cycle carboplatin at AUC 7 as a reasonable alternative for patients with significant risk factors or compliance concerns 19.

Key uncertainties. Long-term (>20-year) secondary malignancy and cardiovascular risk data for carboplatin remain limited. The optimal number of carboplatin cycles (one versus two) and the appropriate risk stratification model (binary versus three-tier) have not been prospectively validated in an RCT with mature follow-up. Time to relapse after carboplatin may be longer than with surveillance, with retrospective data reporting that 15% of relapses occur beyond three years and 3% beyond five years 19.

Controversy 2: One Versus Two Cycles of BEP in Stage I NSGCT

The debate. For clinical stage I NSGCT, lymphovascular invasion (LVI) is among the strongest independent predictors of relapse, with relapse rates reported at approximately 40–50% in LVI-positive versus 15–20% in LVI-negative patients 19—adjuvant bleomycin, etoposide, and cisplatin (BEP) chemotherapy reduces relapse risk dramatically. The unresolved question is whether one cycle is equivalent to two cycles in efficacy while offering substantially lower acute and late toxicity.

Evidence for single-cycle BEP. A community-based prospective study of 490 unselected CS I NSGCT patients receiving single-cycle BEP demonstrated five-year relapse rates of 3% in LVI-positive and 2% in LVI-negative patients; after a median follow-up of eight years, these rates were sustained with no relapses beyond 3.3 years, implying that more than 90% of relapses are prevented by a single cycle 19. A randomized phase III trial comparing two-year recurrence-free survival with adjuvant BEP ×1 versus primary RPLND showed 99.5% versus 91% recurrence-free survival, further establishing single-cycle BEP as highly active 19. Reducing from two to one cycle meaningfully improves the risk-benefit ratio, diminishing cumulative cisplatin nephrotoxicity, bleomycin pulmonary toxicity, etoposide-associated secondary leukemia risk, and ototoxicity.

Evidence for two-cycle BEP. A prospective trial using two cycles of BEP in high-risk LVI-positive patients reported a relapse rate of only 2.7% at median follow-up of 7.9 years, with no adverse effects on fertility or sexual activity in a series of approximately 200 patients 19. The earlier meta-analysis of stage I NSGCT management recommended two cycles of BEP for patients preferring immediate treatment 25. In multiply treated cohorts, relapse after adjuvant BEP has been associated with potentially worse salvage outcomes than de novo metastatic disease, although this evidence derives from retrospective analyses 19.

Key uncertainties. No large RCT has directly compared one versus two cycles of BEP in stage I NSGCT with rigorous stratification by LVI status and embryonal carcinoma predominance. Late toxicity data—particularly cardiac events, renal function decline, secondary malignancy incidence, and sperm recovery—beyond ten years are incompletely characterized for single-cycle BEP. Late relapse patterns and their salvageability after one versus two cycles also remain incompletely defined.

Controversy 3: Primary RPLND Versus Surveillance or Chemotherapy in Stage I NSGCT

The debate. Retroperitoneal lymph node dissection (RPLND) provides complete histologic staging, identifies teratoma or viable disease that may not respond to chemotherapy, and can cure approximately 70% of patients if nodes are negative—but carries perioperative morbidity and the risk of retrograde ejaculation when nerve-sparing is incomplete.

Evidence for primary RPLND. Data from high-volume expert centers report a relapse risk below 15% after primary RPLND: approximately 10% in pathologic stage I (pN0) and below 30% in patients with nodal metastases (pN2) 19. Robot-assisted RPLND (R-RPLND) has emerged as a minimally invasive alternative with encouraging short- to intermediate-term oncologic outcomes in selected series: multicenter series demonstrate two-year RFS of approximately 91%, nodal yields of 20–32 lymph nodes per case, blood loss of approximately 50 mL versus 300–400 mL for open RPLND, and shorter hospital stays (1 versus 5 days) 42. Antegrade ejaculation preservation approaches 86% with unilateral nerve-sparing templates 42. A population-based analysis of 1,988 non-metastatic RPLND cases (National Inpatient Sample, 2000–2015) confirmed that complication rates in population-based settings (23.6%) are 2- to 4-fold higher than those at centers of excellence, emphasizing the critical importance of surgical centralization 8.

Evidence for surveillance or chemotherapy. EAU guidelines note that the role of primary RPLND has substantially diminished given CSS rates exceeding 99% with surveillance, relapse prevention rates above 90% with single-cycle BEP, and the poor reproducibility of RPLND outcomes outside expert centers 19. The Swedish-Norwegian Testicular Cancer Study Group prospective population-based study of 1,384 seminoma patients demonstrated five-year CSS of 99.6% across all management strategies, supporting the view that the choice of modality is less important than cure, with toxicity becoming the dominant decision factor 27. Finnish long-term data confirm that 73% of non-seminoma relapses in stage I disease can be effectively salvaged with chemotherapy 9.

Key uncertainties. Reproducibility of nerve-sparing RPLND outcomes outside high-volume centers remains a central concern, with multi-institutional series reporting higher in-field recurrence rates and complications than single-center data 19. Long-term fertility and sexual function outcomes with robotic versus open RPLND require prospective comparative study. The role of primary R-RPLND in selected stage II seminoma patients as a chemotherapy-sparing strategy (as explored in the PRIMETEST phase 2 trial) is emerging but remains investigational 42.

Controversy 4: Management of Late Relapse and Platinum-Refractory Disease

The debate. Approximately 20% of patients with metastatic GCTs relapse after first-line therapy, and a subset presents with late relapse (>2 years after complete response) or primary platinum-refractory disease—scenarios where standard salvage approaches are less effective and optimal treatment sequencing is contested.

Evidence for high-dose chemotherapy as first salvage. A multicenter retrospective analysis of 283 patients with relapsed or refractory metastatic GCT from 11 international centers demonstrated that high-dose chemotherapy (HD-CTX) with autologous stem cell transplantation (ASCT) as first salvage therapy yielded a two-year overall survival (OS) of 74% and a five-year OS of 63%, compared with 53% and 37%, respectively, when HD-CTX was administered after conventional-dose salvage regimens (P=0.00027) 41. First-salvage HD-CTX was associated with a higher overall response rate (79% versus 60%; P=0.013) and substantially lower grade ≥3 non-hematologic toxicity (78% versus 97%) 41. The International Prognostic Factors Study Group (IPFSG) score was the only independent predictor of OS on multivariable analysis 41. The TI-CE regimen (paclitaxel plus ifosfamide followed by high-dose carboplatin plus etoposide with stem-cell support) demonstrated a five-year DFS of 47% and OS of 52% in a poor-prognosis cohort, with no relapses beyond two years 29. Treatment-related mortality with modern peripheral blood stem cell mobilization and supportive care has declined to below 3% 34.

Evidence for conventional-dose salvage regimens. Standard conventional-dose salvage regimens including TIP (paclitaxel, ifosfamide, and cisplatin) and gemcitabine-oxaliplatin combinations retain activity in platinum-refractory disease. A retrospective TIP series reported favorable responses in 37.5% of patients with cisplatin-refractory GCT, with long-term survivors at 25–113 months 32. Gemcitabine-oxaliplatin with or without paclitaxel achieved disease-free status beyond two years in approximately 11% of multiply relapsed patients, with secondary surgery after partial remission contributing significantly to long-term outcomes 31. For late relapse (>2 years after CR), complete surgical resection remains the treatment of choice when feasible, with chemotherapy used to facilitate resection in initially unresectable cases 35. Patients relapsing after HDCT-ASCT are generally considered incurable, and further therapy is administered with palliative intent 34.

Investigational approaches. Checkpoint inhibitors (pembrolizumab, nivolumab) have demonstrated limited single-agent activity in platinum-refractory GCTs in phase II trials, with tolerability but insufficient clinical response rates to establish them as standard care 38. Mechanisms of cisplatin resistance, including epigenetic alterations, DNA repair pathways, and molecular signaling abnormalities, are under active investigation 33. MicroRNA-371a-3p (miR-371a-3p) has emerged as a promising surveillance and relapse detection biomarker: in a prospective multicenter study of 616 GCT patients and 258 controls, miR-371a-3p demonstrated a sensitivity of 90.1%, specificity of 94.0%, and area under the receiver operating characteristic curve of 0.966 for primary GCT diagnosis, substantially outperforming AFP, beta-hCG, and LDH 39. A Canadian cohort of 151 CS I patients confirmed that miR-371a-3p elevation at relapse was detected in 94.1% of relapsing patients (versus 62% for AFP/beta-hCG) and may precede clinical relapse by a median of three months—though postorchiectomy levels did not predict which patients would relapse 40. Ongoing prospective trials (SWOG-S1823, AGCT1531, CLIMATE ANZUP1906) are validating miR-371a-3p in clinical decision-making frameworks 39.

Summary Table: Leading Controversies, Evidence, and Proposed Study Designs

Clinical Interpretation and Shared Decision-Making

What is established. Testicular cancer is curable across all management strategies for stage I disease, with CSS approaching 99–100% regardless of whether patients receive surveillance, adjuvant carboplatin, RT, BEP chemotherapy, or primary RPLND 192738. Disease-specific survival is therefore not the primary driver of treatment selection; rather, the choice involves weighing relapse risk, toxicity burden, compliance requirements, and patient preferences in young individuals with decades of life expectancy. Surveillance is the preferred initial strategy for the majority of CS I seminoma patients according to NCCN 2025 and EAU 2023 guidelines 192838. For CS I NSGCT without LVI, surveillance is also preferred; for LVI-positive disease, single-cycle BEP represents the current standard with robust relapse prevention data 19.

What remains controversial. The optimal adjuvant strategy for intermediate-risk CS I seminoma (tumor >4 cm or with rete testis invasion)—surveillance versus single-cycle carboplatin—lacks head-to-head long-term comparison data, particularly regarding secondary malignancy risk beyond twenty years. The question of one versus two BEP cycles in LVI-positive NSGCT has not been resolved by a dedicated RCT. Primary RPLND—increasingly performed robotically with favorable perioperative profiles—requires prospective comparison with surveillance and chemotherapy to establish its role in modern risk-adapted care. In platinum-refractory disease, the timing and sequencing of HD-CTX relative to conventional salvage regimens is supported only by retrospective multicenter data, not prospective randomization 41. Checkpoint inhibitors have shown limited single-agent activity in GCTs 38, and novel biomarkers such as miR-371a-3p require standardization and prospective validation before influencing clinical decision-making 3940.

How evidence should inform practice. Shared decision-making must explicitly address four dimensions: (1) individual relapse risk quantified using validated prognostic models (EAU risk stratification models incorporating factors such as tumor size, rete testis invasion, and lymphovascular invasion) 3; (2) the absolute toxicity difference between strategies, including both acute (hematologic, nausea, fatigue) and late effects (secondary malignancy, cardiovascular, renal, auditory) 67; (3) the patient's capacity and willingness to comply with surveillance imaging schedules, given that the MRI-based protocol from TRISST eliminates ionizing radiation while maintaining relapse detection sensitivity 23; and (4) centralization of care, particularly for RPLND, where population-based complication rates exceed those at specialized centers by 2- to 4-fold 8. Pathologic assessment of LVI and rete testis invasion should be rigorously standardized across institutions, as diagnostic variability in these factors directly influences treatment decisions 21. Ultimately, the near-universal curability of stage I testicular cancer demands that clinical decision-making prioritize survivorship—minimizing the cumulative treatment burden while maintaining the extraordinary cure rates that define this disease.